260 related articles for article (PubMed ID: 26233248)
1. Current status of intratumoral therapy for glioblastoma.
Mehta AI; Linninger A; Lesniak MS; Engelhard HH
J Neurooncol; 2015 Oct; 125(1):1-7. PubMed ID: 26233248
[TBL] [Abstract][Full Text] [Related]
2. Convection-enhanced drug delivery for glioblastoma: a review.
D'Amico RS; Aghi MK; Vogelbaum MA; Bruce JN
J Neurooncol; 2021 Feb; 151(3):415-427. PubMed ID: 33611708
[TBL] [Abstract][Full Text] [Related]
3. Imaging of convection enhanced delivery of toxins in humans.
Mehta AI; Choi BD; Raghavan R; Brady M; Friedman AH; Bigner DD; Pastan I; Sampson JH
Toxins (Basel); 2011 Mar; 3(3):201-6. PubMed ID: 22069706
[TBL] [Abstract][Full Text] [Related]
4. Convection-enhanced delivery for the treatment of glioblastoma.
Vogelbaum MA; Aghi MK
Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii3-ii8. PubMed ID: 25746090
[TBL] [Abstract][Full Text] [Related]
5. Use of nanoparticles for drug delivery in glioblastoma multiforme.
Jain KK
Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491
[TBL] [Abstract][Full Text] [Related]
6. Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies.
Jahangiri A; Chin AT; Flanigan PM; Chen R; Bankiewicz K; Aghi MK
J Neurosurg; 2017 Jan; 126(1):191-200. PubMed ID: 27035164
[TBL] [Abstract][Full Text] [Related]
7. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.
Kawakami K; Kawakami M; Kioi M; Husain SR; Puri RK
J Neurosurg; 2004 Dec; 101(6):1004-11. PubMed ID: 15597761
[TBL] [Abstract][Full Text] [Related]
8. A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma.
Barua NU; Hopkins K; Woolley M; O'Sullivan S; Harrison R; Edwards RJ; Bienemann AS; Wyatt MJ; Arshad A; Gill SS
Drug Deliv; 2016; 23(1):167-73. PubMed ID: 24786643
[TBL] [Abstract][Full Text] [Related]
9. Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma.
Bastiancich C; Danhier P; Préat V; Danhier F
J Control Release; 2016 Dec; 243():29-42. PubMed ID: 27693428
[TBL] [Abstract][Full Text] [Related]
10. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
11. Convection-enhanced delivery for glioblastoma: targeted delivery of antitumor therapeutics.
Ung TH; Malone H; Canoll P; Bruce JN
CNS Oncol; 2015; 4(4):225-34. PubMed ID: 26103989
[TBL] [Abstract][Full Text] [Related]
12. Convection-enhanced delivery to achieve widespread distribution of viral vectors: Predicting clinical implementation.
Debinski W; Tatter SB
Curr Opin Mol Ther; 2010 Dec; 12(6):647-53. PubMed ID: 21154156
[TBL] [Abstract][Full Text] [Related]
13. Convection-Enhanced Delivery in the Treatment of Glioblastoma.
Brown CB; Jacobs S; Johnson MP; Southerland C; Threatt S
Semin Oncol Nurs; 2018 Dec; 34(5):494-500. PubMed ID: 30392757
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme.
White E; Bienemann A; Taylor H; Hopkins K; Cameron A; Gill S
Contemp Clin Trials; 2012 Mar; 33(2):320-31. PubMed ID: 22101221
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.
Sampson JH; Akabani G; Friedman AH; Bigner D; Kunwar S; Berger MS; Bankiewicz KS
Neurosurg Focus; 2006 Apr; 20(4):E14. PubMed ID: 16709019
[TBL] [Abstract][Full Text] [Related]
16. Setting the stage: local delivery of cytoreductive agents for the treatment of glioblastoma.
Kalkanis SN
Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii1-ii2. PubMed ID: 25746088
[No Abstract] [Full Text] [Related]
17. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
[TBL] [Abstract][Full Text] [Related]
18. Rethinking Glioblastoma Therapy: MDA-9/Syntenin Targeted Small Molecule.
Das SK; Sarkar D; Cavenee WK; Emdad L; Fisher PB
ACS Chem Neurosci; 2019 Mar; 10(3):1121-1123. PubMed ID: 30681320
[TBL] [Abstract][Full Text] [Related]
19. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
20. Convection-enhanced Delivery of Therapeutics for Malignant Gliomas.
Saito R; Tominaga T
Neurol Med Chir (Tokyo); 2017 Jan; 57(1):8-16. PubMed ID: 27980285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
